✦ LIBER ✦

Population pharmacokinetics of antifibroblast activation protein monoclonal antibody F19 in cancer patients

✍ Scribed by Paul Tanswell; Pilar Garin-Chesa; Wolfgang J. Rettig; Sydney Welt; Chaitanya R. Divgi; Ephraim S. Casper; Ronald D. Finn; Steven M. Larson; Lloyd J. Old; Andrew M. Scott

Book ID: 108640053
Publisher: John Wiley and Sons
Year: 2001
Tongue: English
Weight: 83 KB
Volume: 51
Category: Article
ISSN: 0306-5251
DOI: 10.1111/j.1365-2125.2001.01335.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pharmacokinetics, biodistribution and bi

Pharmacokinetics, biodistribution and biological effects of intravenously administered bispecific monoclonal antibody OC/TR F(ab′)2 in ovarian carcinoma patients

✍ Jacoba G. Tibben; Otto C. Boerman; Leon F. A. G. Massuger; Charles P. T. Schijf; 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 French ⚖ 856 KB

The bispecific monoclonal antibody (biMAb) OC/TR combines the anti-ovarian-cancer reactivity of the MOvl8 monoclonal antibody (MAb) with the reactivity of an anti-CD3 MAb. Pre-clinical studies have indicated that this biMAb is able to redirect the cytolytic activity of T cells towards tumour cells,

Distribution of radiolabelled anti-CA125

Distribution of radiolabelled anti-CA125 monoclonal antibody OC125-F(ab′)2-fragment following resection guided by antibodies (REGAJ) in ovarian cancer patients

✍ Martina M. Uttenreuther-Fischer; Herbert Feistel; Friedrich Wolf; Wolfram Jäger 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 76 KB

Ovarian cancer is a highly malignant tumor of mainly postmenopausal women. The long-term prognosis of this malignancy is largely determined by micrometastasis present at the time of second-look surgery. In general, patients face a poor outcome. New radio-immunoscintigraphic methods to target tumor t

Mechanism-based receptor-binding model t

Mechanism-based receptor-binding model to describe the pharmacokinetic and pharmacodynamic of an anti-α5β1integrin monoclonal antibody (volociximab) in cancer patients

✍ Chee M. Ng; S. Bai; C. H. Takimoto; M. T. Tang; A. W. Tolcher 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 587 KB

Ability of osteoclast formation from per

Ability of osteoclast formation from peripheral monocytes using anti-fusion regulatory protein-1/cd98/4f2 monoclonal antibodies in patients with osteoporosis

✍ Masatoshi Tajima; Yasumitsu Higuchi; Noriki Miyamoto; Shigeomi Higuchi; Morihiro 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 415 KB

## Abstract We investigated the difference in osteoclast formation between patients with osteoporosis and two healthy control groups by inducing it from peripheral blood monocytes with use of anti‐fusion regulatory protein‐1 monoclonal antibody. The group of patients with osteoporosis consisted of

Serum level of cryptic tumor antigens in

Serum level of cryptic tumor antigens in breast cancer patients as determined by two monoclonal antibodies (m85/f36) and its comparison with ca 15-3

✍ Dr. T. Ming; Rodric Constantine; Takuma Nemoto 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 563 KB

An enzyme immunoassay system that measures cryptic epitopes on breast cancer mucinlike antigens (BCM-EIA) was evaluated in a double-blind manner in sera from 58 normal blood donors, 36 sex-and age-matched controls, 36 patients with benign breast diseases, and 47 patients with breast cancer. Two muri

Immunoscintigraphy with 131I-labelled mo

Immunoscintigraphy with 131I-labelled monoclonal antibodies HMFG2 and HMFG1 F(ab')2 versus abdominal CT scan in the detection of residual disease in ovarian cancer patients

✍ D. Pectasides; K. Pateniotis; L. Tzimis; X. Trapalli; P. Natsis; P. Arapantoni; 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 French ⚖ 514 KB

3'I-labelled HMFGl or HMFGl F(ab')2 monoclonal antibody (MAb) was administered intraperitoneally to I S patients with epithelial ovarian cancer who had completed chemotherapy and were in complete or good partial remission. Each patient received 2-3 mCi. Patients were scanned immediately after and un